ArticleESMO real world data and digital oncology2026
Balancing clinical relevance, legal boundaries, and technological solutions: a case-based analysis of secondary use of electronic health records in Sweden.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The secondary use of electronic health records (EHRs) poses legal challenges, particularly when the responsibility for managing EHRs lies with local or regional authorities. This article presents a case-based analysis of the secondary use of EHR data in contexts where data privacy responsibilities are managed regionally in Sweden. Methods and results: Using two distinct purposes for the secondary use of the digital tool Patient Overview Breast Cancer: (i) assessing the uptake of new treatment strategies in a real-world setting for quality assurance, and (ii) evaluating the effectiveness of these strategies in specific patient subgroups with limited evidence for research purposes, the study explored the distinctions between research and quality assurance, the legal implications of each framework, and the potential role of federated learning as a privacy-preserving technological solution. Conclusions: Federated learning offers a promising approach to overcome legal and organizational barriers to secondary use of regional EHRs in Sweden, enabling scalable, clinically meaningful insights for cancer care. However, its effective implementation requires a unified national framework that balances personal integrity with patient safety, supported by regulatory sandboxes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.